Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Single-Arm Phase II Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC

NCT07827079 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.

NCT NCT07827079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07827079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Single-Arm Phase II Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC
Lead sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2024
Completion date
July 1, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (triple negative breast cancer (tnbc)), chemeotherapy